Morgan Stanley Atea Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 488,899 shares of AVIR stock, worth $1.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

488,899

Previous 367,540 33.02%

Holding current value

$1.66 Million

Previous $1.22 Million 34.62%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.17 - $4.02 $384,708 - $487,863	121,359 Added 33.02%	488,899 $1.64 Million
Q2 2024 Oct 17, 2024	SELL	$3.31 - $4.04 $122,797 - $149,879	-37,099 Reduced 9.17%	367,540 $1.22 Million
Q2 2024 Aug 14, 2024	SELL	$3.31 - $4.04 $122,797 - $149,879	-37,099 Reduced 9.17%	367,540 $1.22 Million
Q1 2024 Oct 17, 2024	BUY	$3.09 - $4.56 $114,635 - $169,171	37,099 Added 10.09%	404,639 $1.63 Million
Q1 2024 Aug 16, 2024	SELL	$3.09 - $4.56 $9,322 - $13,757	-3,017 Reduced 0.74%	404,639 $1.63 Million
Q1 2024 May 15, 2024	SELL	$3.09 - $4.56 $9,322 - $13,757	-3,017 Reduced 0.74%	404,639 $1.63 Million
Q4 2023 Aug 16, 2024	BUY	$2.8 - $3.35 $112,324 - $134,388	40,116 Added 10.91%	407,656 $1.24 Million
Q4 2023 Feb 13, 2024	BUY	$2.8 - $3.35 $399,179 - $477,589	142,564 Added 53.78%	407,656 $1.24 Million
Q3 2023 Nov 15, 2023	SELL	$3.0 - $3.79 $493,212 - $623,091	-164,404 Reduced 38.28%	265,092 $795,000
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $153,081 - $241,306	-47,689 Reduced 9.99%	429,496 $1.61 Million
Q1 2023 May 15, 2023	BUY	$3.0 - $4.97 $113,853 - $188,616	37,951 Added 8.64%	477,185 $1.6 Million
Q4 2022 Feb 14, 2023	SELL	$4.35 - $6.17 $251,195 - $356,292	-57,746 Reduced 11.62%	439,234 $2.11 Million
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $573,507 - $918,238	104,464 Added 26.61%	496,980 $2.83 Million
Q2 2022 Oct 27, 2022	SELL	$5.33 - $8.18 $192,439 - $295,338	-36,105 Reduced 8.42%	392,516 $2.79 Million
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $192,439 - $295,338	-36,105 Reduced 8.42%	392,516 $2.79 Million
Q1 2022 Oct 27, 2022	BUY	$5.5 - $9.19 $198,577 - $331,804	36,105 Added 9.2%	428,621 $3.1 Million
Q1 2022 May 13, 2022	SELL	$5.5 - $9.19 $1.18 Million - $1.97 Million	-214,121 Reduced 33.31%	428,621 $3.1 Million
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $1.53 Million - $8.92 Million	200,056 Added 45.19%	642,742 $5.75 Million
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $9.44 Million - $15.5 Million	442,686 New	442,686 $15.5 Million

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $283M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account